Navigation Links
Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Date:1/9/2012

ALBUQUERQUE, N.M., Jan. 9, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the launch of Avise SLE, which aids in the diagnosis of lupus (Systemic Lupus Erythematosus).

Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE diagnosis. Specifically, the panel includes testing of ANA, dsDNA, Avise MCV, EC4d and BC4d. The Avise SLE diagnostic differentiates itself by using cell-bound complements because of their increased performance over soluble complements which helps to accurately and consistently diagnose SLE.

Avise SLE is most impactful when ordered as a first step in patient treatment to help physicians with diagnosis by providing:

  • Efficiency - 5 individual markers, 1 blood draw
  • Confidence in Diagnosis - From a panel that rules-in SLE and rules-out other rheumatic diseases
  • Increased Accuracy - Using CB-CAPs technology to achieve 78% sensitivity and 87% specificity for other diseases/97% specificity for normal/healthy patients
  • Convenience - We provide kits, pay shipping costs and return test results in 7 business days

 

"Exagen is excited to offer a breakthrough diagnostic that uses CB-CAPs technology to help accurately determine if a patient has lupus," said Ron Rocca, President and CEO. "Because diagnosing lupus is so difficult and early diagnosis is critical in avoiding major organ damage, developing an accurate diagnostic to fill the unmet need for rheumatologists was a top priority. We have been able to do that with Avise SLE and are pleased to take part in helping physicians gain control over this serious disease."

About Exagen

Exagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA registered, CAP certified laboratory with a growing menu of proprietary, internally developed tests focused in the areas of Rheumatology and Gastroenterology. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.  Using uniquely powerful Coperna® discovery technology, Exagen identifies and validates small sets of genomic markers which are used to create meaningful, easily interpreted diagnostic tests for clinical use. For more information, please visit www.Exagen.com or www.AviseTest.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Eric Tornoe Joins Exagen Diagnostics as President and COO
2. Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program
3. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
4. S.E.D. Labs to be Acquired by Quest Diagnostics
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
8. Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
9. Quest Diagnostics Initiates CEO Succession Process
10. Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
11. Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):